Sugi Predict

Sugi Predict / Targets / NQO2

NQO2

Ribosyldihydronicotinamide dehydrogenase [quinone] · P16083 · NQO2 on Sugi Atlas →

109,806 patent compounds predicted against NQO2, 70,767 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL135600 SCHEMBL135600 1.00 18/20
SCHEMBL135601 SCHEMBL135601 1.00 18/20
SCHEMBL138000 SCHEMBL138000 0.48 14/20
SCHEMBL136496 SCHEMBL136496 0.64 13/20
SCHEMBL182949 SCHEMBL182949 0.66 11/20
SCHEMBL183009 SCHEMBL183009 0.57 8/20
SCHEMBL135119 SCHEMBL135119 0.65 7/20
SCHEMBL132847 SCHEMBL132847 0.62 7/20
Phenazine Phenazine (SCHEMBL94396) 0.48 7/20
Phenazine Phenazine (SCHEMBL9049) 0.69 6/20
SCHEMBL188079 SCHEMBL188079 0.62 6/20
SCHEMBL144288 SCHEMBL144288 0.49 6/20
SCHEMBL110643 SCHEMBL110643 0.48 6/20
SCHEMBL76177 SCHEMBL76177 0.43 6/20
SCHEMBL25712 SCHEMBL25712 0.42 6/20
Pterostilbene Pterostilbene (SCHEMBL20063) 1.00 5/20
Phenazine Phenazine (SCHEMBL182948) 0.61 5/20
SCHEMBL23844 SCHEMBL23844 0.44 5/20
SCHEMBL50667 SCHEMBL50667 0.43 5/20
Iodomelatonin Iodomelatonin (SCHEMBL163451) 1.00 4/20

Clinical trials — most relevant to NQO2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
cindilizumab + Bevacizumab + Coenzyme I for Injection in Unresectable Hepatocellular Carcinoma PHASE4UNKNOWN
Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression PHASE2/PHASE3NOT_YET_RECRUITING
Primaquine Double Dose for Radical Cure of Plasmodium Vivax in Colombia PHASE2/PHASE3WITHDRAWN
IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer PHASE2UNKNOWN
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy PHASE2ACTIVE_NOT_RECRUITING
Mitochondrial Dysfunction in the Pathophysiology and Treatment of Bipolar Disorder PHASE2WITHDRAWN
Senolytics to Improve Osteoporosis Therapy PHASE2ACTIVE_NOT_RECRUITING
Trial of Nicotinamide Riboside and Co-enzyme Q10 in Chronic Kidney Disease PHASE2COMPLETED
pCCLCHIM-p47 (Lentiviral Vector Transduced CD34 Plus Cells) in Patients With p47 Autosomal Recessive Chronic Granulomatous Disease (AR-CGD) PHASE1/PHASE2ENROLLING_BY_INVITATION
Effects of Nicotinamide Riboside on the Clinical Outcome of Covid-19 in the Elderly PHASE2WITHDRAWN
A Study to Evaluate Vitamin B3 Derivative to Treat Mitochondrial Myopathy PHASE2ACTIVE_NOT_RECRUITING
Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults PHASE1RECRUITING
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside nanUNKNOWN
Lung Mucus Hypersecretion and NQO1 nanCOMPLETED
The Safety and Efficacy Study of RiaGev in Healthy Adults nanUNKNOWN
Mitoquines in COPD nanUNKNOWN
Mechanistic Study of Nicotinamide Riboside on NAD+ Biology in Individuals With Combined Pulmonary Hypertension nanRECRUITING
Effect of Subtle Energy Transmission and Tao Calligraphy Mindfulness Practice on Mitochondrial DNA in Peripheral Blood Leukocytes nanNOT_YET_RECRUITING
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA nanRECRUITING
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression nanCOMPLETED
Sirtuin1 in COVID19 Patients nanUNKNOWN
Testing of NBIA Genes: Analysis of Genetic Heterogeneity and Validation of Mitochondrial Markers for Assessing Causality of Sequence Variants. nanCOMPLETED
Quantitative Assessment of the Etiologies of Megalencephaly Associated With a Detectable Tumor Risk nanNOT_YET_RECRUITING
Tissue Sample Study for Mitochondrial Disorders nanENROLLING_BY_INVITATION
Mechanistic Studies of Teriflunomide in RRMS nanCOMPLETED
Covid-19: Possible Role of Neutrophil Extracellular Traps nanUNKNOWN
Role of Metabolic Enzymes in Non-Melanoma Skin Cancer nanCOMPLETED
Molecular Epidemiology of Dioxin-Related Illness in Seveso nanCOMPLETED
Outcome of Use of a Novel Modulator of Oxidative Phosphorylation on Kidney Function in Patients With Progressive Chronic Kidney Disease nanCOMPLETED
Natural History Study for Patients With Nemaline Myopathy in Spain nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a NQO2 binder may also engage these)

ProteinNameSimilarity
Q5RBB9 — 1.000 Q5RBB9 →
Q6AY80 — 0.999 Q6AY80 →
Q9JI75 — 0.997 Q9JI75 →
P05982 — 0.988 P05982 →
Q64669 — 0.987 Q64669 →
Q5RD31 — 0.986 Q5RD31 →
NQO1 NAD(P)H dehydrogenase [quinone] 1 0.981 landscape →
Q8CHK7 — 0.981 Q8CHK7 →
P0AEY6 — 0.971 P0AEY6 →
P0AEY7 — 0.971 P0AEY7 →
Q5RBT4 — 0.970 Q5RBT4 →
PRMT5 Protein arginine N-methyltransferase 5 0.970 landscape →
Q28479 — 0.970 Q28479 →
Q8H9D2 — 0.969 Q8H9D2 →
P0AEY5 — 0.969 P0AEY5 →
A7YW45 — 0.968 A7YW45 →
Q5R698 — 0.967 Q5R698 →
Q68FX0 — 0.967 Q68FX0 →
Q5R5E9 — 0.967 Q5R5E9 →
ARG2 Arginase-2, mitochondrial 0.967 landscape →
F4ZGF2 — 0.966 F4ZGF2 →
Q4R5M3 — 0.966 Q4R5M3 →
A8E657 — 0.966 A8E657 →
Q9UDR5 — 0.966 Q9UDR5 →
RBBP9 Serine hydrolase RBBP9 0.966 landscape →
G6PD Glucose-6-phosphate 1-dehydrogenase 0.966 landscape →
Q9I509 — 0.966 Q9I509 →
P05370 — 0.965 P05370 →
B9M4V3 — 0.965 B9M4V3 →
O55044 — 0.965 O55044 →